Efficacy and safety of ultrasound guided radiofrequency ablation for treating low risk papillary thyroid microcarcinoma: a prospective study.

Related Articles

Efficacy and safety of ultrasound guided radiofrequency ablation for treating low risk papillary thyroid microcarcinoma: a prospective study.

Thyroid. 2016 Jul 22;

Authors: Zhang M, Luo Y, Zhang Y, Tang J

Abstract
BACKGROUND: Papillary thyroid microcarcinoma (PTMC) has a high incidence and a good prognosis. Surgical operation for all PTMC might be an overtreatment. The objective of our study was to evaluate the efficacy and safety of ultrasound (US)-guided radiofrequency ablation (RFA) for treating low risk PTMC.
METHODS: 98 PTMC in 92 patients were included in our study. US and contrast-enhanced ultrasound (CEUS) examinations were performed before ablation. RFA was performed using the moving shot technique. The ablation area exceeded the tumor edge to prevent marginal residue and recurrence. Patients were followed at one, three, six, and twelve months and every six months thereafter. US and CEUS examinations were used to evaluate the ablation area. At 3 months after ablation, US-guided core needle biopsy (CNB) was performed in the center, at the edge of the ablation area, and in the surrounding thyroid parenchyma, respectively, to exclude recurrence.
RESULTS: The mean tumor volume was 118.8±106.9 mm3. The mean volume reduction ratio was 0.47±0.27, 0.19±0.16, 0.08±0.11, 0.04±0.10 and 0 at one month, 3 months, 6 months, 12 months and 18 month after RFA respectively. Significant differences of the volume reduction ratio were found between every two follow-up times before 6 months (P<0.01), and no significant differences of the volume reduction ratio were found between 6 months and after 12 months (P=0.42). Of all the nodules, 10 (41.7%) resolved in 6 months and 23 (95.8%) resolved in 12 months. No residual or recurrent tumor tissue was detected in RFA area or in residual thyroid tissue during follow up. No suspicious metastatic lymph nodes were detected. The histological pathology results of US-guided CNB confirmed no recurrent tumor. No major complications were encountered.
CONCLUSIONS: RFA can effectively eliminate low risk PTMC with a very small complication rate. RFA may be an alternative strategy for the therapy of PTMC.

PMID: 27445090 [PubMed - as supplied by publisher]

from #ENT-PubMed via ola Kala on Inoreader http://ift.tt/2ajBCFE
via IFTTT